These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 28003361)

  • 1. Thioredoxin-1 Selectively Activates Transglutaminase 2 in the Extracellular Matrix of the Small Intestine: IMPLICATIONS FOR CELIAC DISEASE.
    Plugis NM; Palanski BA; Weng CH; Albertelli M; Khosla C
    J Biol Chem; 2017 Feb; 292(5):2000-2008. PubMed ID: 28003361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of extracellular transglutaminase 2 by thioredoxin.
    Jin X; Stamnaes J; Klöck C; DiRaimondo TR; Sollid LM; Khosla C
    J Biol Chem; 2011 Oct; 286(43):37866-73. PubMed ID: 21908620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endoplasmic reticulum-resident protein 57 (ERp57) oxidatively inactivates human transglutaminase 2.
    Yi MC; Melkonian AV; Ousey JA; Khosla C
    J Biol Chem; 2018 Feb; 293(8):2640-2649. PubMed ID: 29305423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transglutaminase 2 strongly binds to an extracellular matrix component other than fibronectin via its second C-terminal beta-barrel domain.
    Stamnaes J; Cardoso I; Iversen R; Sollid LM
    FEBS J; 2016 Nov; 283(21):3994-4010. PubMed ID: 27685605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thioredoxin is involved in endothelial cell extracellular transglutaminase 2 activation mediated by celiac disease patient IgA.
    Antonella Nadalutti C; Korponay-Szabo IR; Kaukinen K; Wang Z; Griffin M; Mäki M; Lindfors K
    PLoS One; 2013; 8(10):e77277. PubMed ID: 24130874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unexpected role of surface transglutaminase type II in celiac disease.
    Maiuri L; Ciacci C; Ricciardelli I; Vacca L; Raia V; Rispo A; Griffin M; Issekutz T; Quaratino S; Londei M
    Gastroenterology; 2005 Nov; 129(5):1400-13. PubMed ID: 16285941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin 4 is inactivated via selective disulfide-bond reduction by extracellular thioredoxin.
    Plugis NM; Weng N; Zhao Q; Palanski BA; Maecker HT; Habtezion A; Khosla C
    Proc Natl Acad Sci U S A; 2018 Aug; 115(35):8781-8786. PubMed ID: 30104382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gliadin T cell epitope selection by tissue transglutaminase in celiac disease. Role of enzyme specificity and pH influence on the transamidation versus deamidation process.
    Fleckenstein B; Molberg Ø; Qiao SW; Schmid DG; von der Mülbe F; Elgstøen K; Jung G; Sollid LM
    J Biol Chem; 2002 Sep; 277(37):34109-16. PubMed ID: 12093810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural and mechanistic analysis of Ca
    Sewa AS; Besser HA; Mathews II; Khosla C
    Proc Natl Acad Sci U S A; 2024 Jul; 121(28):e2407066121. PubMed ID: 38959038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective inhibition of extracellular thioredoxin by asymmetric disulfides.
    DiRaimondo TR; Plugis NM; Jin X; Khosla C
    J Med Chem; 2013 Feb; 56(3):1301-10. PubMed ID: 23327656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cosilencing Intestinal Transglutaminase-2 and Interleukin-15 Using Gelatin-Based Nanoparticles in an in Vitro Model of Celiac Disease.
    Attarwala H; Clausen V; Chaturvedi P; Amiji MM
    Mol Pharm; 2017 Sep; 14(9):3036-3044. PubMed ID: 28737923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substrates, inhibitors, and probes of mammalian transglutaminase 2.
    Zhuang R; Khosla C
    Anal Biochem; 2020 Feb; 591():113560. PubMed ID: 31874171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Celiac anti-type 2 transglutaminase antibodies induce differential effects in fibroblasts from celiac disease patients and from healthy subjects.
    Paolella G; Lepretti M; Barone MV; Nanayakkara M; Di Zenzo M; Sblattero D; Auricchio S; Esposito C; Caputo I
    Amino Acids; 2017 Mar; 49(3):541-550. PubMed ID: 27613408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Redox regulation of transglutaminase 2 activity.
    Stamnaes J; Pinkas DM; Fleckenstein B; Khosla C; Sollid LM
    J Biol Chem; 2010 Aug; 285(33):25402-9. PubMed ID: 20547769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation and inhibition of transglutaminase 2 in mice.
    Dafik L; Albertelli M; Stamnaes J; Sollid LM; Khosla C
    PLoS One; 2012; 7(2):e30642. PubMed ID: 22319575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transglutaminase 2 dysfunctions in the development of autoimmune disorders: celiac disease and TG2-/- mouse.
    Szondy Z; Korponay-Szabó I; Király R; Fésüs L
    Adv Enzymol Relat Areas Mol Biol; 2011; 78():295-345. PubMed ID: 22220477
    [No Abstract]   [Full Text] [Related]  

  • 17. In Vivo Measurement of Redox-Regulated TG2 Activity.
    Melkonian AV; Weng N; Palanski BA; Khosla C
    Methods Mol Biol; 2019; 1967():263-274. PubMed ID: 31069776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single conformational transglutaminase 2 epitope contributed by three domains is critical for celiac antibody binding and effects.
    Simon-Vecsei Z; Király R; Bagossi P; Tóth B; Dahlbom I; Caja S; Csosz É; Lindfors K; Sblattero D; Nemes É; Mäki M; Fésüs L; Korponay-Szabó IR
    Proc Natl Acad Sci U S A; 2012 Jan; 109(2):431-6. PubMed ID: 22198767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An unprecedented dual antagonist and agonist of human Transglutaminase 2.
    Yi MC; Palanski BA; Quintero SA; Plugis NM; Khosla C
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4922-4926. PubMed ID: 26004580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Constitutive Differential Features of Type 2 Transglutaminase in Cells Derived from Celiac Patients and from Healthy Subjects.
    Paolella G; Nanayakkara M; Sposito S; Lepretti M; Auricchio S; Esposito C; Barone MV; Martucciello S; Caputo I
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32059410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.